These results demonstrated that ANGPTL4 might be an important regulatory factor in the control of decreased MMP-9 expression by suppressing the binding activities of AP-1, Sp-1, and NF-κB​​ in DATS-treated bladder cancer cells. This evidence concerns the gene SP1 and urinary bladder cancer.